Author

Kashish Patel

Observed names: K.R. Patel, Kashish C Patel, Patel, Kashish

Institutions: University of North Carolina at Chapel Hill, Carolina Institute for NanoMedicine

Observed institutions: University of North Carolina at Chapel Hill, Carolina Institute for NanoMedicine, UNC Lineberger Comprehensive Cancer Center

OpenAlex ID: A5114207486

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

2024 · Aaron S. Mansfield, Jun Vivien Yin, et al. · Lung Cancer · 18

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

2021 · D.P. Petrylak, U.N. Vaishampayan, et al. · ESMO Open · 10

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer

2025 · Li Chen, Andrew T. Lucas, et al. · Clinical and Translational Science · 4

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer

2026 · Zamboni, William C., O'Connor, Claire, et al. · UNC Libraries

Pharmacokinetics of Intravaginal, Self-Administered Artesunate Vaginal Inserts Among Healthy Women in Kenya

2026 · Annum Sadana, Sabine J Yessayan, et al. · medRxiv

Pharmacologic and pharmacometric studies of factors affecting the pharmacokinetics and pharmacodynamics of antibody drug conjugate anetumab ravtansine in patients with solid tumors.

2025 · Li Chen, Andrew T. Lucas, et al. · Journal of Clinical Oncology

A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)

2019 · D.P. Petrylak, U.N. Vaishampayan, et al. · Annals of Oncology

Works count: 7

Citation count: 32

H-index: 3

I10-index: 2